Dr. Fergusson’s clinical research interests are mainly in the field of transfusion medicine with a focus on transfusion alternatives and the effectiveness of blood products. His research interests also extend to the methodology and ethics of clinical trials and systematic reviews. Dr. Fergusson is the co-lead of the Rethinking Clinical Trials (REaCT) Program which performs practical patient-focused research that ensures that patients receive optimal, safe, cost-effective treatment. It includes the pragmatic evaluation of standard, usual care interventions using efficient informed consent, efficient routinely collected electronic administrative and clinical data, and immediate implementation of findings into routine practice.